Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00088790 · ClinicalTrials.gov registry record · Phase 1
AZD5438 in Patients With Advanced Solid Malignancies
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00088790: Completed Phase 1 study, sponsored by AstraZeneca.
NCT00088790 is a Phase 1 study that has completed, run by AstraZeneca. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00088790, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
Purpose of this study is to assess the safety and tolerability of AZD5438 given orally to patients with advanced solid malignancies A review of the emerging clinical tolerability and exposure data from this study in conjunction with preclinical and the available clinical pharmacodynamic data relating to AZD5438, led to a decision by AstraZeneca that the development of AZD5438 as a potential anti-cancer agent would be discontinued.
Interventions
- DRUG AZD5438
Trial Details
| Field | Value |
|---|---|
| Start Date | 2004-07 |
| Est. Completion | 2005-12 |
| Phase | Phase 1 |
What the finished NCT00088790 record still lists
NCT00088790 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which AZD5438 is the first listed.
NCT00088790 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00088790 about?
NCT00088790 is a clinical study titled "AZD5438 in Patients With Advanced Solid Malignancies". Purpose of this study is to assess the safety and tolerability of AZD5438 given orally to patients with advanced solid malignancies A review of the emerging clinical tolerability and exposure data from this study in conjunction with preclinical and the available clinical pharmacodynamic data relatin...
What is the current status of trial NCT00088790?
This trial is currently completed. It is a Phase 1 study. The study started on 2004-07. Estimated completion is 2005-12.
What interventions are being tested in trial NCT00088790?
The interventions under investigation include: AZD5438 (DRUG).
Who is sponsoring clinical trial NCT00088790?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia